The Neonatal Hemorrhagic Risk Assessment in Thrombocytopenia Study-2
Status: Recruiting
Location: See all (8) locations...
Study Type: Observational
SUMMARY
This is a prospective observational study designed to evaluate Immature Platelet Fraction or Immature Platelet Count and Platelet Function Analyzer-100/200 Closure Time-ADP (in vitro bleeding time) as markers of bleeding risk in thrombocytopenic preterm neonates admitted to the Neonatal Intensive Care Unit.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 1 day
Healthy Volunteers: f
View:
• Have a gestational age \<32 weeks and a birth weight ≥500 grams;
• Have a platelet count \<100 x 109/L; and
• Have a parent/guardian willing to provide written informed consent.
Locations
United States
Massachusetts
Beth Israel Deaconess Medical Center
NOT_YET_RECRUITING
Boston
Boston Children's Hospital
RECRUITING
Boston
Utah
Intermountain Medical Center
NOT_YET_RECRUITING
Murray
Utah Valley Hospital
NOT_YET_RECRUITING
Provo
Other Locations
Netherlands
Amsterdam University Medical Centre
NOT_YET_RECRUITING
Amsterdam
Leiden University Medical Center
NOT_YET_RECRUITING
Leiden
Sweden
Karolinska University Hospital Huddinge campus
RECRUITING
Huddinge
Karolinska University Hospital Solna campus, Astrid Lindgren Children's Hospital
RECRUITING
Stockholm
Contact Information
Primary
Emöke Deschmann, MD, PhD
emoke.deschmann@regionstockholm.se
+46 73 539 5575
Backup
Martha Sola-Visner, MD
martha.sola-visner@childrens.harvard.edu
617-919-4845
Time Frame
Start Date: 2021-06-15
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 250
Related Therapeutic Areas
Sponsors
Collaborators: Boston Children's Hospital, Karolinska University Hospital, Region Stockholm, National Heart, Lung, and Blood Institute (NHLBI), Harvard Medical School (HMS and HSDM), The Swedish Society of Medicine
Leads: Karolinska Institutet